Lirum Therapeutics' LX-101 IGF-1R-Targeted Peptide Payload Conjugate Shows Antitumor Activity in Ewing Sarcoma at AACR 2026
Lirum Therapeutics announced preclinical data at AACR 2026 demonstrating antitumor activity of LX-101, an IGF-1R–targeted peptide-payload conjugate, in Ewing sarcoma patient-derived xenograft models. As a monotherapy, LX-101 showed meaningful single-agent activity and demonstrated synergy when combined with PI3K or mTOR inhibition. The compound was previously granted FDA "Study May Proceed" authorization for inclusion in the RAPID platform clinical trial for relapsed/refractory Ewing sarcoma and desmoplastic small round cell tumor (DSRCT).